LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Kura Oncology Inc

Closed

SectorHealthcare

6.01 1.52

Overview

Share price change

24h

Current

Min

5.88

Max

6.2

Key metrics

By Trading Economics

Income

-38M

-57M

Sales

-40M

14M

EPS

-0.66

Profit margin

-407.067

Employees

192

EBITDA

-48M

-65M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+279.83% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

1.4M

527M

Previous open

4.49

Previous close

6.01

News Sentiment

By Acuity

50%

50%

177 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Kura Oncology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 maj 2025, 19:39 UTC

Major Market Movers

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 maj 2025, 23:18 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 maj 2025, 22:30 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- Update

16 maj 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 maj 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 maj 2025, 21:54 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 maj 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 maj 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 maj 2025, 21:17 UTC

Top News

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 maj 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 maj 2025, 20:55 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 maj 2025, 20:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

16 maj 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 maj 2025, 20:37 UTC

Top News

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 maj 2025, 20:33 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 maj 2025, 20:30 UTC

Acquisitions, Mergers, Takeovers

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 maj 2025, 20:18 UTC

Top News

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 maj 2025, 20:16 UTC

Top News

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 maj 2025, 20:15 UTC

Earnings

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 maj 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Henry Schein: William K. Daniel Joins Board

16 maj 2025, 20:10 UTC

Acquisitions, Mergers, Takeovers

Henry Schein: Strategic Investment by KKR Completed

16 maj 2025, 20:05 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 maj 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 maj 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 maj 2025, 18:51 UTC

Top News

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 maj 2025, 18:41 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 maj 2025, 18:37 UTC

Market Talk

Gold Futures End Week on Negative Note -- Market Talk

16 maj 2025, 18:35 UTC

Top News

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 maj 2025, 18:32 UTC

Top News

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 maj 2025, 18:28 UTC

Market Talk

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

279.83% upside

12 Months Forecast

Average 22.6 USD  279.83%

High 40 USD

Low 10 USD

Based on 13 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

5.575 / 6.6Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

177 / 382 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.